ArticleDermatology and therapy2021

Efficacy and Safety of Netakimab, A Novel Anti-IL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of A 54-Week Randomized Double-Blind Placebo-Controlled PLANETA Clinical Trial.

Luís Puig et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.